title: Recovery of stromal stem cells in bone sarcoma patients after chemotherapy: implication for cell-based therapy in bone defect reconstruction.
abstract: Bone sarcomas, such as osteosarcoma (OS) or Ewing sarcoma (ES), frequently arise in the intramedullary region of long bones. Patients affected by bone sarcomas are treated with preoperative aggressive chemotherapy immediately after diagnosis. After chemotherapy, patients undergo surgery that frequently entails the excision of wide bone segments. If a large segment of the bone is lost (defined as a critical defect) the patient undergoes bone reconstruction. Because bone marrow derived stromal stem cells (SSC) offer great promise for cell-based regenerative medicine in bone reconstruction, we investigated whether SSC could be isolated from chemotherapy-treated bone sarcoma patients. We also investigated whether chemotherapy modified SSC differentiation capability. We studied 9 SSC derived from OS and ES patients that had undergone chemotherapy and 5 SSC derived from bone sarcoma patients that had not undergone chemotherapy. SSC could be obtained from all the patients analyzed regardless of whether the patients received chemotherapy or not. Our results also showed that post-chemotherapy SSC can be cultured and expanded ex vivo, these cells retained the ability to differentiate toward the osteogenic lineage in vitro. In conclusion, our results support that SSC cells can be obtained from bone sarcoma patients that undergo chemotherapy and suggest that SSC can be used for cell-based bone reconstruction techniques in bone sarcoma patients treated with preoperative chemotherapy.
authors.affiliation: Oncological Research Laboratory, Istituti Ortopedici Rizzoli, Via di Barbiano 1/10, I-40136 Bologna (BO), Italy.
authors.forename: Amira
authors.initials: A
authors.lastname: Beccheroni
authors.forename: Enrico
authors.initials: E
authors.lastname: Lucarelli
authors.forename: Davide
authors.initials: D
authors.lastname: Donati
authors.forename: Luca
authors.initials: L
authors.lastname: Sangiorgi
authors.forename: Silvia
authors.initials: S
authors.lastname: Capponcelli
authors.forename: Marco
authors.initials: M
authors.lastname: Gorini
authors.forename: Annarosa
authors.initials: A
authors.lastname: Zambon Bertoja
authors.forename: Roberto
authors.initials: R
authors.lastname: Giardino
authors.forename: Mario
authors.initials: M
authors.lastname: Mercuri
authors.forename: Stefano
authors.initials: S
authors.lastname: Ferrari
authors.forename: Gaetano
authors.initials: G
authors.lastname: Bacci
authors.forename: Piero
authors.initials: P
authors.lastname: Picci
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D002454:Cell Differentiation; D002455:Cell Division; D002478:Cells, Cultured; D002648:Child; D002813:Chondrosarcoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D005260:Female; D005870:Giant Cell Tumors / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008297:Male; D014411:Neoplastic Stem Cells / Q000473:pathology*; D010006:Osteoblasts / Q000378:metabolism / Q000473:pathology*; D012516:Osteosarcoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D012512:Sarcoma, Ewing / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D017154:Stromal Cells / Q000473:pathology*